Study of Awareness and Detection of Familial Hypercholesterolemia (CASCADE-FH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01960244 |
Recruitment Status :
Recruiting
First Posted : October 10, 2013
Last Update Posted : April 26, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Hypercholesterolemia |

Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 5000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 3 Years |
Official Title: | CASCADE FH Registry (CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia Registry) |
Study Start Date : | October 2013 |
Estimated Primary Completion Date : | December 2025 |
Estimated Study Completion Date : | December 2025 |

Group/Cohort |
---|
hypercholesterolemia
familial hypercholesterolemia
|
- Promote awareness of FH to increase the number of identified FH patients, reaching optimal level of disease management; target treatment levels for LDL cholesterol. [ Time Frame: 3 Years ]therapy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Online Patient Enrollment Inclusion Criteria:
- Patients with existing clinical diagnosis of FH;
- Patients with genetic mutation of FH;
- Patients with an initial (pretreatment) LDL level >190 mg/dL or total cholesterol >300 mg/dL;
- Patients currently taking a lipid-lowering medication and have an LDL >124 mg/dL or total cholesterol >195 mg/dL.
Clinic Patient Enrollment Inclusion Criteria:
- Patients with existing clinical diagnosis of FH using one of the three clinical diagnostic (US MedPed Program Criteria, Simon Broome Register Criteria with diagnosis of "Probable", Dutch Lipid Clinic Network Diagnostic Criteria with diagnosis of "Probable")tools for FH; or
- Patients with genetic mutation of FH
Exclusion Criteria:
- Patients will be excluded from participation in the registry when a known medical condition other than FH that is thought to contribute to hyperlipidemia (i.e., untreated hypothyroidism, nephrotic syndrome, cholestasis hypopituitarism).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01960244
Contact: MARY CARD, MBA | 6265834674 | mcc@thefhfoundation.org |
United States, California | |
Stanford Center for Inherited Cardiovascular Diseases | Recruiting |
Palo Alto, California, United States, 94304 | |
Contact: Hannah Ison 650-575-9589 hison@stanfordhealthcare.org | |
Principal Investigator: Joshua Knowles, MD |
Study Director: | Katherine Wilemon | FHFoundation |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | The Familial Hypercholesterolemia Foundation |
ClinicalTrials.gov Identifier: | NCT01960244 |
Other Study ID Numbers: |
Pro00045568 |
First Posted: | October 10, 2013 Key Record Dates |
Last Update Posted: | April 26, 2022 |
Last Verified: | October 2021 |
familial hypercholesterolemia FH |
Hyperlipoproteinemia Type II Hypercholesterolemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders |
Metabolic Diseases Lipid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Hyperlipoproteinemias |